Part 01 · The Question→Part 02 · The Record→Part 03 · The File
← All Case Files
Inspection Case File · CF03 · Quality Control Laboratory

OOS Investigation Disposition: The 483 Most Teams Don't See Coming.

A documented deviation. A signed CAPA. A closed investigation. And a single question, asked on day two of inspection, that the file does not answer.

What you'll see in this case file
  • The exact 483 observation language
  • The five required authorization fields
  • A complete reference DDR record
  • The blank template for your facility
See What Defensible Looks Like → Free to read. No payment to continue.
Citation · 21 CFR 211.192 ICH · Q10 Used by Quality leaders preparing for FDA inspections
The Scene

Day two of the inspection.

. The investigator pulls OOS Investigation OOS-2024-0073. Lisinopril Tablets 20 mg, Lot 2024-0418. Dissolution result fell below USP specification at the 30-minute timepoint.

The Phase IA laboratory investigation found an HPLC injection volume anomaly. The investigator concluded laboratory error. The lot was retested under controlled conditions. The retest passed. The lot was released.

The investigator turns to the conclusion.

Investigator
"Laboratory error — assignable cause identified."
She reads the conclusion twice. Then she sets the file down and looks up.
Investigator
"Who authorized the conclusion that this was laboratory error? What evidence specifically ruled out manufacturing causes? What evidence ruled out a content uniformity issue? And on what documented basis was the original failing result invalidated for retest?"
She listens to the verbal answer. Then she asks for the documented reasoning.
Pause

Most QA teams answer this question verbally. The file does not contain the documented reasoning. That is the gap.

Skip ahead to the record format →
Why this matters now

FDA OOS guidance has been the source of repeated 483 observations for over a decade. The pattern is consistent: laboratory error determined, manufacturing causes not formally eliminated, original result invalidated without documented basis.

What the file contained

The OOS investigation report was complete. The HPLC system check was thorough. The injection volume anomaly was real. The retest passed.

By every internal measure, the disposition was sound. Phase IA was executed. The assignable cause was identified. The OOS Coordinator signed the report.

What the file contained was the conclusion.

What the file did not contain was the decision.

An assignable cause was identified. A retest was performed. A pass was recorded. But the rationale for treating the HPLC anomaly as sufficient cause to invalidate the original measurement, the documented exclusion of manufacturing causes, and the named individual who authorized the disposition decision are not in the file.

The conclusion belongs in the file. The decision belongs in the record.

What the investigator is evaluating
21 CFR 211.192 does not ask whether the laboratory found an anomaly. It asks whether the OOS disposition was reached on a documented basis that includes elimination of manufacturing causes.

FDA OOS guidance is explicit: an assignable laboratory cause may justify invalidation of the original result, but the investigation must formally consider and document elimination of manufacturing causes before that conclusion is authorized.

The investigation must demonstrate — in writing, contemporaneous with the disposition — that the assignable cause is supported by direct evidence, that manufacturing causes have been formally evaluated and ruled out, and that the named authorizing individual reviewed both before approving disposition.

An HPLC anomaly is data. An HPLC anomaly is not, on its own, a documented OOS disposition.

Investigator
"I am not asking whether the retest passed. I am asking whether the laboratory error determination was authorized — and on what evidentiary basis."
The QC Manager cannot produce the record.
The Gap

The retest may have been correct. The file does not show the work behind invalidating the original.

The OOS file documents the HPLC anomaly. It does not document who decided this constituted laboratory error, on what evidence, against what alternatives, and under what authority.

Ready to see the record format?
See the five fields the investigator expects to find →
The 483
"Failure to document the rationale used to justify the conclusion that the original out-of-specification result was invalid, including the specific evidence that supported invalidation and the reasoning by which alternative root causes were excluded. The investigation record concludes the disposition but does not reconstruct the decision logic that produced it."
21 CFR 211.192 — applied regulatory framework.
Continued · Part 02 of 03

That 483 was avoidable.

See the record that prevents it.

The five fields the investigator expects to find. The alternative-causes evaluation that distinguishes a decision from a signature. A complete reference example from the Vancomycin scenario.

Show Me the Record →
✓ Free to read · No payment required to continue

Used by Quality and Validation leaders preparing for FDA and EMA inspections. Built around 21 CFR 211.192 and ICH Q9.